Professor Marc-Emmanuel Dumas, PhD MEng MSc BEng BSc FRSB FRSC
Marc-Emmanuel Dumas is Chair in Systems Medicine, jointly appointed between the Department of Metabolism, Digestion and Reproduction and the National Heart and Lung Institute. He is head of the Section of Biomolecular Medicine, which hosts state-of-the-art equipment dedicated to metabolomics, crystallisation science and tissue culture. He founded and is director of Imperial's Microbiome Network, a cross-faculty multidisciplinary network of excellence made of >60 PIs and their groups to consolidate research, teaching and public engagement activities around the microbiome.
Research led by Professor Dumas targets innovative metabolomics approaches to better understand the key challenges in the integrative control of metabolism, blending genomics and microbiomics in systems medicine. He focusses mostly on the role of the microbiome (but not limited to) in metabolic and cardiorespiratory diseases as well as in chronic inflammation, including neuroinflammation, and certain types of cancers.
Since Sept 2020, he is CNRS investigator and group leader at UMR8199 in Lille, France. He also holds an Adjunct Professorship at McGill University's Genome Innovation Centre and Department of Human Genetics in Montréal, Canada.
et al., 2021, Combinatorial, additive and dose-dependent drug-microbiome associations, Nature, Vol:600, ISSN:0028-0836, Pages:500-+
et al., 2021, A prenylated dsRNA sensor protects against severe COVID-19, Science, Vol:374, ISSN:0036-8075, Pages:579-+
et al., 2021, Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study, The Lancet, Vol:398, ISSN:0140-6736, Pages:223-237
COVID-19 Host Genetics Initiative, 2021, Mapping the human genetic architecture of COVID-19, Nature, Vol:600, ISSN:0028-0836, Pages:472-477
et al., 2021, Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health., Gut, Vol:70, ISSN:0017-5749, Pages:2105-2114
et al., 2020, Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology, Nature Communications, Vol:11
et al., 2020, Statin therapy is associated with lower prevalence of gut microbiota dysbiosis, Nature, Vol:581, ISSN:0028-0836, Pages:310-+
et al., 2018, Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women., Nat Med, Vol:24, Pages:1070-1080
et al., 2018, Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota, Microbiome, Vol:6, ISSN:2049-2618
et al., 2017, A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nature Medicine, Vol:23, ISSN:1546-170X, Pages:107-113
et al., 2015, Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome, Cell Metabolism, Vol:22, ISSN:1932-7420, Pages:320-331
et al., 2014, Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the Xenobiotic sensor PXR and toll-like receptor 4, Immunity, Vol:41, ISSN:1074-7613, Pages:296-310
et al., 2007, Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models, Nature Genetics, Vol:39, ISSN:1061-4036, Pages:666-672
et al., 2006, Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice, Proceedings of the National Academy of Sciences of the United States of America, Vol:103, ISSN:0027-8424, Pages:12511-12516